Related Experiment Video
Updated: Aug 7, 2026
Electroconvulsive Seizures in Rats and Fractionation of Their Hippocampi to Examine Seizure-induced Changes in Postsynaptic Density Proteins
Published on: August 15, 2017
Prolonged vigabatrin treatment modifies developmental changes of GABA(A)-receptor binding in young children with
C Juhász1, O Muzik, D C Chugani
1Department of Pediatrics, Children's Hospital of Michigan, The Detroit Medical Center, Wayne State University School of Medicine, Detroit, Michigan 48201, USA.
Insights
Vigabatrin (VGB) treatment in epileptic children significantly reduces GABA(A)-receptor binding in the brain's cortex and cerebellum. Further research is needed to understand the consequences of this effect on brain development.
Area of Science:
- Neuroscience
- Pharmacology
- Pediatric Neurology
Background:
- Epilepsy treatment often involves antiepileptic drugs (AEDs) that modulate neurotransmitter systems.
- The GABAergic system, particularly GABA(A)-receptors, plays a crucial role in brain development and function.
- Vigabatrin (VGB) is an AED that increases GABA levels, but its long-term effects on developing brains are not fully understood.
Purpose of the Study:
- To investigate the impact of prolonged vigabatrin (VGB) treatment on in vivo GABA(A)-receptor binding in children with epilepsy.
- To determine if VGB interferes with normal age-related changes in GABA(A)-receptor binding during brain development.
Main Methods:
- Utilized [11C]flumazenil (FMZ) positron emission tomography (PET) imaging in 15 children (aged 1-8 years) with epilepsy.
- Compared FMZ binding (volume of distribution, VD) in seven VGB-treated children versus eight children on other non-GABAergic AEDs.
- Quantified absolute PET data to represent FMZ ligand binding in brain tissue.
Main Results:
- Children treated with VGB showed significantly lower hemispheric FMZ VD values compared to the non-VGB group, even after controlling for age.
- VGB treatment led to significantly reduced FMZ VD in cortical regions and the cerebellum, but not in the thalamus or basal ganglia.
- No significant drug effects were observed for carbamazepine or valproate, suggesting a specific effect of VGB.
Conclusions:
- Prolonged vigabatrin (VGB) treatment decreases GABA(A)-receptor binding in the developing brain's cortex and cerebellum in epileptic children.
- This VGB-induced effect on GABA(A)-receptor binding may have implications for neurodevelopmental plasticity.
- Further studies are warranted to explore the reversibility and functional consequences of this age-specific drug effect.
Purpose:
To determine whether prolonged treatment with vigabatrin (VGB), an antiepileptic drug (AED) that acts by elevating brain gamma-aminobutyric acid (GABA) levels, interferes with age-related changes of in vivo GABA(A)-receptor binding in children with epilepsy.
Methods:
Using [11C]flumazenil (FMZ)-positron emission tomography (PET) imaging, 15 children (aged 1-8 years) with medically intractable epilepsy were studied. Seven of these children were treated with VGB (1,000-2,500 mg/day) for > or =3 months before the FMZ-PET study. The remaining eight patients were medicated with other drugs that are known not to act directly on the GABAergic system. Absolute quantification of PET data was performed by using the volume of distribution (VD) of FMZ in brain tissue representing FMZ ligand binding.
Results:
After controlling for age, hemispheric FMZ VD values were significantly lower in children treated with VGB as compared with the non-VGB group (p = 0.012). Regional FMZ VD values of the VGB-treated patients were significantly lower in all cortical regions and the cerebellum, whereas the difference was not significant in the thalamus and basal ganglia. No significant drug effect or drug-by-region interaction could be determined when the patients were separated according to treatment with carbamazepine (p = 0.97) or valproate (p = 0.55).
Conclusions:
VGB induces a decrease in GABA(A)-receptor binding in the cortex and cerebellum of the developing epileptic brain. A similar effect of other drugs and substances of abuse targeting the GABAergic system may be hypothesized. Because of the important role of the GABAergic system in developmental plasticity, the reversibility and functional consequences of this age-specific drug effect should be further studied.
More Related Videos
07:01Electrophoretic Delivery of γ-aminobutyric Acid (GABA) into Epileptic Focus Prevents Seizures in Mice
Published on: May 16, 2019
08:04Identification and Classification of Position-specific GABAA Receptor Subunit Missense Variants for Their Role In Hippocampal Pyramidal Neurons
Published on: June 6, 2025
Related Concept Videos
01:24Epilepsy and Seizures: Overview
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
01:08Antiepileptic Drugs: Sodium Channel Blockers
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
01:14Antiepileptic Drugs: Glutamate Antagonists
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
01:20Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...